Pfizer Axes Staff And Five Pre-Clinical Biosimilars To Fund Late-Stage Innovative Programs

 
• By Dean Rudge
AxeWood
Pfizer has taken the axe to five pre-clinical biosimilars, in order to better fund innovative programs • Source: Shutterstock

More from Strategy

More from Business